A Phase 1, Combined Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MEDI4166 in Subjects With Type 2 Diabetes Mellitus (T2D)
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs MEDI 4166 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors MedImmune
- 09 Jul 2017 Status changed from active, no longer recruiting to completed.
- 13 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2016 Planned number of patients changed from 124 to 100.